Cancer and necroptosis: friend or foe?

被引:63
|
作者
Philipp, Stephan [1 ]
Sosna, Justyna [1 ]
Adam, Dieter [1 ]
机构
[1] Univ Kiel, Inst Immunol, Michaelisstr 5, D-24105 Kiel, Germany
关键词
Regulated necrosis; Necroptosis; Cancer; TRAIL; TNF; PROGRAMMED CELL-DEATH; TUMOR-NECROSIS-FACTOR; MIXED LINEAGE KINASE; DOMAIN-LIKE PROTEIN; TRAIL RECEPTOR; TNF-ALPHA; APOPTOSIS; RIP3; EXPRESSION; FADD;
D O I
10.1007/s00018-016-2193-2
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Regulated cell death is one major factor to ensure homoeostasis in multicellular organisms. For decades, apoptosis was considered as the sole form of regulated cell death, whereas necrosis was believed to be accidental and unregulated. Due to this view, research on necrosis was somewhat neglected, especially in the field of anti-cancer treatment. However, new interest in necrosis has been sparked by the recent discovery of different forms of necrosis that show indeed regulated pathways. More and more studies now address the molecular pathways of regulated necrosis and its connections within the cellular signaling networks. Necroptosis, a subform of regulated necrosis, has so far hardly been focused on with regard to a future treatment of cancer patients and may emerge as a novel and effective approach to eliminate tumor cells. However, and similar to apoptosis, tumor cells can develop resistances against necroptosis to ensure their own survival. In this context, new molecules that enhance necroptosis are currently being identified to overcome such resistances. This review discusses cancer and necroptosis as friends or foes, i.e. the options to exploit necroptosis in anti-cancer therapies ("foes"), but also potential limitations that may block or actually cause necroptosis to act in a protumoral manner ("friends"). The balance between these two possible roles will determine whether necroptosis can indeed be used as a promising tool for early diagnosis of tumors, prevention of metastasis and anti-cancer treatment.
引用
收藏
页码:2183 / 2193
页数:11
相关论文
共 50 条
  • [21] Sunitinib in breast cancer: Friend or foe
    Cardoso, Fatima
    Senkus-Konefka, Elzbieta
    BREAST, 2009, 18 (04): : 211 - 212
  • [22] Corticosteroids and Prostate Cancer: Friend or Foe?
    Geynisman, Daniel M.
    Szmulewitz, Russell Z.
    Plimack, Elizabeth R.
    EUROPEAN UROLOGY, 2015, 67 (05) : 874 - 875
  • [23] Rho GTPases in cancer: friend or foe?
    Svensmark, Julius H.
    Brakebusch, Cord
    ONCOGENE, 2019, 38 (50) : 7447 - 7456
  • [24] Sulfonylurea derivatives and cancer, friend or foe?
    Hendriks, Anne M.
    Schrijnders, Dennis
    Kleefstra, Nanne
    de Vries, Elisabeth G. E.
    Bilo, Henk J. G.
    Jalving, Mathilde
    Landman, Gijs W. D.
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2019, 861
  • [25] Ferroptosis: friend or foe in cancer immunotherapy?
    Demuynck, Robin
    Efimova, Iuliia
    Catanzaro, Elena
    Krysko, Dmitri, V
    ONCOIMMUNOLOGY, 2023, 12 (01):
  • [26] Autophagy: Is it cancer's friend or foe?
    Marx, J
    SCIENCE, 2006, 312 (5777) : 1160 - 1161
  • [27] Alternative nutrition in cancer: friend or foe?
    Holmes, S
    JOURNAL OF THE ROYAL SOCIETY FOR THE PROMOTION OF HEALTH, 2003, 123 (02): : 76 - 76
  • [28] Autophagy: Cancer's Friend or Foe?
    Bhutia, Sujit K.
    Mukhopadhyay, Subhadip
    Sinha, Niharika
    Das, Durgesh Nandini
    Panda, Prashanta Kumar
    Patra, Samir K.
    Maiti, Tapas K.
    Mandal, Mahitosh
    Dent, Paul
    Wang, Xiang-Yang
    Das, Swadesh K.
    Sarkar, Devanand
    Fisher, Paul B.
    ADVANCES IN CANCER RESEARCH, VOL 118, 2013, 118 : 61 - 95
  • [29] Neutrophil Engulfment in Cancer: Friend or Foe?
    Lu, Tong
    Li, Wei
    CANCERS, 2025, 17 (03)
  • [30] Neutral Sphingomyelinases in Cancer: Friend or Foe?
    Clarke, Christopher J.
    SPHINGOLIPIDS IN CANCER, 2018, 140 : 97 - 119